Published in Medical Letter on the CDC and FDA, February 12th, 2006
"Tenofovir disoproxil fumarate (DF) is a promising agent for use in pediatric salvage therapy, because of its tolerability, efficacy, and resistance profile," scientists in the United States report.
According to R. Hazra and colleagues at the U.S. National Institutes of Health, "We designed this study to provide preliminary pediatric...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.